Right. Just like they stated with their obesity drug before the initial Adcom. They led investors to believe that safety was stellar. Management is full of baloney. ARNA is junk.
You do realize that the full details of the sale have yet to be released, right? Wait until they're out. You'll see other offers were made.
I wouldn't sell those options tomorrow. They are going to be crushed and he'll take an absolutely huge loss. Better to hold for a week or two and hope another bidder steps in. He'll feel even worse if he sells tomorrow and a bidding war emerges.
LOL. Arena is one of the biggest biotech terds out there. How dumb do you think investors are?
Always possible that another biotech steps forward and ups the ante. I had the same thing happen to me with TSRX. It sucks, but I learned that when buying options for a hot biotech likely to get bought out to stick with ITM calls or calls just barely OTM. Hope it works out for you.
Report out a month or two back mentioned 10 pharmas were vying for RCPT. Frankly, I believe it. This company has a blockbuster on its hands.
Well, we know GILD has a massive cash hoard, and it was reported that they previously made an offer. TEVA, though, has been the most aggressive according to reports.
I'm biased though because I bought GILD calls today. (But not because I thought they'd buy RCPT.)
Sannthera's valuation is way too high for their drug. Its effects are nowhere near as helpful as SRPT's, yet they have a higher market cap. No way, Jose.
I'm actually the one who started that twitter argument, but I agree that it's a moot point. And I think we'll get priority review.
Calm down, Frances. We're like 3% off the high after undergoing a normal, healthy pullback. We don't need to get sold until eteplirsen is approved. Now go change your diaper.
I don't have a problem with that. Thig's statement seemed to suggest he was going to rub it in the FDA's face in order to make them feel stupid. That won't work. It'll just #$%$ them off. Hasn't helped in the past; won't help now. I think it's fine to send them anecdotal evidence, but there is no point benefit to saying, "See? I told you so!"